Core Scientific Inc vs 22nd Century Group Inc — how do they compare? Core Scientific Inc trades at $15.32 (market cap $4.94B), while 22nd Century Group Inc trades at $0.84 (market cap $621.67K). The key difference: Core Scientific Inc is far larger — about 7946.3× 22nd Century Group Inc's market cap, and Core Scientific Inc is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and 22nd Century Group Inc for 32 Days on average.
| CORZ | XXII | |
|---|---|---|
Market Cap | $4.94B | $621.67K |
Volume | 15,630,800 | 45,625 |
Sector | Technology | Consumer Staples |
52-Week High | $29.16 | $483.00 |
52-Week Low | $13.57 | $0.80 |
Typical Hold Time | 20 Days | 32 Days |
Enterprise Value | $7.46B | -$3.69M |
Signals from Pluang's Aura AI — not financial advice
Core Scientific (CORZ) trades at $15.30, down 4.02% today amid bearish technical signals and negative earnings momentum. The stock faces fundamental challenges with a net income margin of -324.9% and three consecutive quarterly earnings misses. However, analyst sentiment remains overwhelmingly positive with 86% buy ratings and a $32.75 consensus price target, while recent executive appointments and AI infrastructure developments provide potential catalysts.
Despite current financial struggles, CORZ shows potential through its pivot to AI data center services and strong institutional support. Key risks include persistent negative profitability, high capital expenditures, and cryptocurrency market volatility. The significant gap between current price and analyst targets suggests upside potential if the company executes its AI infrastructure strategy successfully.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →